Genetic variations in EIF2AK3 are associated with neurocognitive impairment in people living with HIV

Cagla Akay-Espinoza, Sarah Bond, Beth A. Dombroski, Asha Kallianpur, Ajay Bharti, Donald R. Franklin, Gerard D. Schellenberg, Robert K. Heaton, Igor Grant, Ronald J. Ellis, Scott L. Letendre, Kelly L. Jordan-Sciutto
doi: https://doi.org/10.1101/2022.04.20.22273997

Abstract

Coding and noncoding single-nucleotide variants (SNVs) of EIF2AK3, which encodes an integrated stress response (ISR) kinase, may play a role in neurodegenerative disorders. We used a candidate gene approach to determine the correlation of EIF2AK3 SNVs with neurocognitive (NC) impairment (NCI), which can persist with viral suppression from antiretroviral therapy (ART) in people with HIV (PWH). This retrospective study of prospectively collected data included participants of the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) cohort, after excluding participants with severe neuropsychiatric comorbidities. Genome-wide data previously obtained in the CHARTER cohort participants (n=1,047) were analyzed to interrogate the association of three noncoding EIF2AK3 SNVs with the continuous global deficit score (GDS) and global NCI (GDS≥0.5). Targeted sequencing (TS) was performed in 992 participants with available genomic DNA to determine the association of three coding EIF2AK3 SNVs with GDS and NCI. Analyses included univariable and multivariable methods such as analysis of variance and regression. Multivariable models covaried demographic, disease-associated, and treatment characteristics. The cohort characteristics were as follows: median age, 43.1 years; females, 22.8%; European ancestry, 41%; median CD4+ T cell counts, 175/µL (nadir) and 428/µL (current). At first assessment, 70.5% used ART and 68.3% of these had plasma HIV RNA ≤ 200 copies/mL. A minority of participants had at least one risk allele for rs6739095 (T,41.7%), rs1913671 (C,41.4%), and rs11684404 (C,39.4%). All three noncoding EIF2AK3 SNVs were associated with significantly worse GDS and more NCI (all p<0.05). By TS, fewer participants had at least one risk allele for rs1805165 (G,30.9%), rs867529 (G,30.9%), and rs13045 (A,41.2%). Homozygosity for all three coding SNVs was associated with significantly worse GDS and more NCI (all p<0.001). By multivariable analysis, the rs13045 A risk allele, current ART use, and Beck Depression Inventory-II (BDI) > 13 were independently associated with GDS and NCI (p<0.001). The other two coding SNVs did not significantly correlate with GDS or NCI after including rs13045 in the model. The coding EIF2AK3 SNVs were specifically associated with worse performance in executive functioning, motor functioning, learning, and verbal fluency. Coding and non-coding SNVs of EIF2AK3 were associated with global NC and domain-specific performance. The effects were small-to-medium in size but were present in multivariable analyses. Specific SNVs in EIF2AK3 may be an important component of genetic vulnerability to NC complications in PWH. Identification of host factors that predict NCI could allow for earlier interventions, including those directly modulating the ISR, to improve NC outcomes.

Introduction

Despite vastly improved health outcomes with antiretroviral therapy (ART), up to 50% of people with human immunodeficiency virus (HIV) infection (PWH) continue to experience neurocognitive (NC) impairment (NCI) and other neurological disorders 1; 2. Milder forms of NCI persist and may worsen even when HIV RNA is suppressed by ART 2-5. Progression to more disabling NC disorders is more likely in PWH with mild, even asymptomatic, NCI than in unimpaired PWH 6. Accumulating evidence also supports that neuropsychiatric disorders such as depression and aging-related disorders are more common in PWH 7-14.

Suppressive ART is currently the only proven intervention to prevent or improve NCI in PWH 15-17. Several factors increase the risk for NCI, including lower nadir CD4+ T cell count, metabolic syndrome, hepatitis C virus (HCV) coinfection, depression, and older age 17-28. To date, clinical trials have not identified interventions that further improve on the benefits of ART. Mechanistic biomarkers of NC vulnerability should enable earlier diagnosis of NCI and new therapeutic interventions 29.

While some of the risk factors associated with NCI, such as sex and genetic factors, may be known at the time of diagnosis and can be considered time-invariable, others, such as metabolic syndrome, arise later and can vary over time. While knowledge of risk factors is paramount for the successful prevention and management of NCI, identification of host factors that are predictive for these at the time of, or soon after, HIV diagnosis, could have an impact by providing opportunities to implement adjunctive therapies. Conversely, genetic vulnerability is well studied in several neurodegenerative disorders, but less is known about the potential contribution of genetic risk factors to HIV-associated NCI 30-37.

Several of the risk factors for NCI, including HIV replication, older age, and persistent inflammation, induce the integrated stress response (ISR), a ubiquitous cellular response pathway used by cells in the brain and elsewhere to resolve cellular stress and reach homeostasis 38-51. The ISR involves the activation of at least one of four sensor kinases, GCN2, HRI, PKR, and PKR-like endoplasmic reticulum kinase (PERK), in response to amino acid or heme deprivation, viral infection, and endoplasmic reticulum (ER) stress, with subsequent activation via multimerization and autophosphorylation. When active, the common target of all four ISR kinases is eukaryotic initiation factor 2α (eIF2α) which, when phosphorylated, attenuates global protein synthesis while upregulating the translation of a subset of transcripts involved in establishing protein homeostasis, such as ATF4 and genes involved in the antioxidant response 39; 52; 53. When ISR activation is prolonged, genes involved in cell death including caspase 4 and CCAAT/enhancer-binding proteins (C/EBP) homologous protein (CHOP) can be induced 38; 39; 54-56; thus, transient ISR activation may be protective but chronic activation may result in cell damage or death 57-61. Importantly, we and others have shown ISR activation, including the increased expression of phospho-PERK and phospho-eIF2 α (peIF2α), to be present in PWH with NCI as well as in people without HIV who have Alzheimer’s disease (AD), Huntington Disease, or progressive supranuclear palsy (PSP) 62-68.

Intriguingly, recent studies by Schellenberg and colleagues raise the possibility that variants of EIF2AK3, which encodes PERK, may also be a genetic risk factor in neurodegenerative diseases based on the finding that a specific protein-coding haplotype of EIF2AK3 was associated with increased risk for PSP through genome-wide association and postmortem studies 69; 70. To date, three major coding haplotypes of EIF2AK3 have been identified; of these, the common haplotypes are A (64%) and B (29%) based on 26 genome-wide association studies (GWASs) (http://www.ncbi.nlm.nih.gov/SNV/), whereas the less common D haplotype has a frequency of 6% in the 1000 Genome data (Table 1). Schellenberg et al. showed that EIF2AK3 haplotype B harboring minor alleles of three nonsynonymous single nucleotide variants (SNVs), including rs7571971, in the coding region was associated with increased PSP risk 69; 70. The authors also reported that the rs7571971 risk allele was in strong linkage disequilibrium with the haplotype B-coding SNVs. Another study demonstrated that lymphoblastoid cell lines derived from EIF2AK3 haplotype B-expressing individuals had enhanced PERK activity compared to those lines derived from EIF2AK3 haplotype A-expressing individuals 71; furthermore, PERK inhibition by small-molecule inhibitors or by modulation of eIF2α phosphorylation was reported to alleviate neurological deficits and pathology in small animal models of several neurodegenerative diseases 72-79.

View this table:
Table 1.

Major haplotypes of EIF2AK3

In light of the evidence showing increased or sustained PERK activity as detrimental to several critical cellular pathways in a wide range of conditions and based on the possibility of a link between specific minor alleles of EIF2AK3 and neurodegenerative diseases with features shared by NCI in PWH, we hypothesized that minor EIF2AK3 alleles such as haplotype B-associated SNVs are a risk factor for NCI in PWH. The objective of the present study was to determine whether minor alleles of EIF2AK3 SNVs, which were previously reported to be associated with neurodegeneration, correlated with worse NC performance in PWH.

Materials and Methods

Study cohort

This was a retrospective study of data prospectively collected from 1,047 PWH who were assessed in the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) cohort 2 between 2003 and 2015 and who had genomic DNA available for analysis. Participants who had severe neuropsychiatric comorbidities (e.g., untreated schizophrenia or seizure disorder) were excluded. All participants were comprehensively evaluated with neuromedical and NC assessments at least once, and 566 participants were assessed at least twice (median 7 assessments, interquartile range 4-11). Blood was collected by venipuncture and cerebrospinal fluid (CSF) was collected by lumbar puncture. All study procedures, including genetic testing, were approved by the University of California San Diego Human Research Protections Program, and all participants provided written informed consent for the study procedures, including future use of data, biospecimens, and genetic data.

Genomic data were analyzed in two phases. The first phase included the genome-wide data of1,047 participants in the CHARTER cohort. The data were queried for three noncoding SNVs in EIF2AK3 (rs6739095, rs1913671, rs11684404), which were previously reported to be in linkage disequilibrium with the three coding SNVs in EIF2AK3. In parallel, targeted sequencing (TS) was performed in 992 of the 1,047 individuals with available genomic DNA to determine the genotypes of three coding SNVs in EIF2AK3 (rs867529, rs1805165, and rs13045), which determine the A, B, and D haplotypes of EIF2AK3.

Targeted sequencing

Genomic DNA samples of the 992 individuals were analyzed using TaqMan SNV genotyping assays (Life Technologies) for rs867529, rs1805165, and rs13045. The assays were performed by polymerase chain reaction according to the previously published conditions 70. Genotypes were visualized and called using a 7900HT Fast Real Time PCR system and the allelic discrimination function of the Sequence Detection System V.2.4 (Applied Biosystems, Waltham, MA, USA).

Neuropsychiatric Assessment

All participants completed standardized, comprehensive neuropsychological assessments of seven cognitive domains that are commonly affected by HIV (learning, recall, motor function, executive function, working memory, speed of information processing, and verbal fluency) 80. The best available normative standards corrected for the effects of age, education, sex, and race/ethnicity. Test scores were converted to demographically corrected standard T scores, which were then converted into deficit scores. The deficit scores across the entre battery were then averaged to derive a Global Deficit Score (GDS), which ranges from 0 to 5, with higher scores indicating poorer NC performance 81. A GDS value ≥ 0.5 indicates NCI. Depressive symptoms were assessed by the Beck Depression Inventory Second Edition (BDI-II), a validated survey of 21 questions that assess the intensity, severity and depth of depressive symptoms.82 Higher BDI-II values indicate more depressive symptoms with a value > 13 indicating at least mild depression.

Statistical Analysis

To assess explanatory variables for impaired vs unimpaired participants in the cohorts, categorical data were compared using Pearson’s chi-square test, and continuous data were compared using Student’s t test. Univariable and multivariable methods, including logistic and linear regression, were used to determine the association of the noncoding and coding SNVs with demographic characteristics (e.g., age, sex, and ancestry), disease-related variables (e.g., plasma and cerebrospinal fluid (CSF) HIV RNA, nadir CD4+ T cell count, comorbidity (e.g., depression, HCV coinfection), treatment status (e.g., ART use), and NC performance, including global deficit score (GDS), global NCI, and domain-specific deficit scores (DDSs). To account for type I error in the analyses of multiple variables associated with GDS and NCI, the false discovery rate approach was used. Akaike Information Criterion and backward selection were used in multivariable regression. All statistical analyses were performed using JMP Pro version 15.0 (SAS Institute, Cary, NC, USA).

Results

The characteristics of the participants

Table 2 summarizes the characteristics of the 1,047 individuals who had data on noncoding EIF2AK3 SNVs. Briefly, the mean age was 43.1 years, 22.8% of the cohort were female, and 41% had European ancestry. Most participants had AIDS (60.7%) and were categorized as having only “minimal” neuropsychiatric comorbidities (64.1%). The median CD4+ T cell counts were 175/µL (nadir) and 428/µL (current). At the first assessment, 70.5% used ART and 68.3% of these had plasma HIV RNA levels ≤ 200 copies/mL.

View this table:
Table 2.

Characteristics of the participants according to the neurocognitive impairment status

Consistent with prior reports from CHARTER, analyses identified that NCI (n=384, 37.4%) was associated with AIDS (65.6% vs 58.2% in the 663 participants without NCI, p = 0.021), ART use (76.4% vs 67.4%, p = 0.002), and lower nadir CD4+ T cell count (150 vs 190/µL, p = 0.028), and more than minimal comorbidities (70.4% vs 53.1%, p < 0.001).

Regarding the noncoding SNVs, 41.7% of the cohort had at least one T minor allele for rs6739095, 41.4% of the cohort had at least one C minor allele for rs1913671, and 39.4% of the cohort had at least one C minor allele for rs11684404. The frequencies of the minor alleles of the three noncoding SNVs reflected those reported in the general population (Table S1). The concordance among the three minor alleles of the three noncoding SNVs was also high in the CHARTER cohort (Table S2), in agreement with previous GWAS findings.

Minor alleles of noncoding EIF2AK3 SNVs are associated with worse GDS and NCI

We first examined the association of noncoding EIF2AK3 SNVs with GDS in the GWAS dataset. As shown in Figure 1, we found that the minor alleles of all three noncoding SNVs were associated with worse GDS and NCI in a dose-dependent manner. For example, the mean GDS values were 0.43 (TT), 0.50 (CT), and 0.56 (CC) for the rs11684404 C risk allele (Fig. 1A, p = 0.0016). The frequency of NCI was also significantly higher in CC homozygotes than in TT homozygotes for rs11684404 (Fig. 1D, 46.3% vs 32.3%, p = 0.0262). Similarly, the rs6739095 T and rs1913671 C risk alleles were associated with GDS as well as with NCI (Fig. 1B, 1C, 1E, 1F).

Figure 1.
Figure 1.

Association of noncoding EIF2AK3 SNVs with GDS (A–C) and NCI (D–E) in the GWAS cohort

GDS, global deficit score; NIC, neurocognitive impairment; SNV, single nucleotide variant

* p < 0.05, analysis of variance; # p < 0.05, Cochran–Armitage test

Minor alleles of noncoding EIF2AK3 SNVs are associated with performance in specific NC ability domains

Emerging data from recent studies including CHARTER and the MACS/WIHS Combined Cohort Study (MWCCS) support that several indicators such as sex and inflammation are associated with deficits in specific NC domains, such as delayed recall or working memory 11; 83-87. We analyzed the associations of the three noncoding EIF2AK3 SNVs with deficits in NC domains in the CHARTER GWAS dataset. As shown in Table 3, the minor alleles of all three noncoding SNVs were associated with deficits in executive functioning (p < 0.001), verbal fluency (p < 0.05), motor function (p < 0.05), and possibly learning (p values, 0.038 to 0.054).

View this table:
Table 3.

Association of noncoding EIF2AK3 SNVs with domain-specific scores

Minor alleles of noncoding EIF2AK3 SNVs are independently associated with GDS and NCI

Multiple linear regression analysis was conducted to explore the association of the noncoding EIF2AK3 SNVs and the HIV and host factors previously shown to be related to GDS. The analysis revealed that the minor allele of rs11684404 remained significantly associated with GDS, along with ART use and neuropsychiatric comorbidities (R2 = 0.08, p < 0.0001) (Table 4), whereas the minor alleles of the other two noncoding EIF2AK3 SNVs did not remain significantly associated with GDS after accounting for the influence of rs11684404. In contrast, multiple logistic regression analysis identified that NCI was associated with the minor allele of rs6739095, but not rs11684404, as well as with ART use, neuropsychiatric comorbidities, and HCV seropositivity (R2 = 0.04, p < 0.0001) (Table 4).

View this table:
Table 4.

Multivariable analysis of the CHARTER dataset

Minor alleles of coding EIF2AK3 SNVs are associated with worse GDS and NCI

Based on our analyses indicating associations of noncoding EIF2AK3 SNVs with GDS and NCI, we next analyzed the minor alleles of three coding EIF2AK3 SNVs, which were previously shown to be associated with increased risk of PSP69; 70. The characteristics of this TS sub-cohort, which included 992 participants with available genomic DNA for analysis, are summarized in Table S3. Risk alleles were again present in a substantial minority: at least one A allele for rs13045 in 41.3%, at least one G allele for rs867529 in 30.9%, and at least one G allele for rs1805165 in 30.9%. The frequencies of the minor alleles of these three SNVs are consistent with their reported frequencies across the 26 published GWASs (Table S4). However, the concordance among the three coding SNVs was different than that observed among the three noncoding SNVs. Specifically, rs867529 and rs1805165 were 100% concordant whereas each exhibited 88.3% concordance with rs13045 (Table S5). Even with this difference in concordance, the minor alleles of all three coding SNVs were also significantly associated with GDS and NCI in a dose-dependent manner, as shown in Figure 2.

Figure 2.
Figure 2.

Association of coding EIF2AK3 SNVs with GDS (A–C) and NCI (D–E) in the TS cohort

* p < 0.05, analysis of variance; # p < 0.05, Cochran–Armitage test

Minor alleles of coding EIF2AK3 SNVs are associated with deficits in cognitive domains

Our analyses to investigate the associations of the three coding EIF2AK3 SNVs with deficits in specific NC domains in the TS cohort revealed distinct patterns, as shown in Table 5. Specifically, the minor allele of rs13045 was associated with domain-specific deficits in executive functioning (p = 0.0131), learning (p = 0.0213), and motor domains (p = 0.0116) whereas the minor alleles of rs867529 and rs1805165 were significantly associated with domain-specific deficits in verbal fluency (p = 0.0025) and motor domains (p = 0.0078).

View this table:
Table 5.

Association of coding EIF2AK3 SNVs with domain-specific scores

Minor alleles of coding EIF2AK3 SNVs are associated with increased CSF levels of IL-6

Based on studies finding that IL-6 concentrations in blood and CSF are a biomarker of inflammation that is associated with NCI in PWH 88, we assessed the relationship of the coding EIF2AK3 SNVs with this biomarker in participants with CSF IL-6 concentrations that were previously quantified by immunoassay and stored in the CHARTER data repository (n = 534). The CSF IL-6 levels did not significantly differ between those with and without NC impairment (Fig. 3A). The minor alleles of all three coding EIF2AK3 SNVs were significantly associated with higher IL-6 in CSF (Figure 3B, 3C; rs13045: p = 0.024, rs867529: p = 0.011, and rs1805165: p = 0.011; data not shown for rs1805165). In contrast, the minor alleles of these coding SNVs were not associated with IL-6 concentration in blood plasma among participants with available data (n = 144; data not shown).

Figure 3.
Figure 3.

Association of NCI (A) and two coding EIF2AK3 SNVs (B, C) with CSF IL-6 levels in a subset of the study cohort with available data

* p < 0.05, analysis of variance

Minor allele of rs13045 is independently associated with GDS and NCI

Our multiple logistic regression analysis comparing the coding EIF2AK3 SNVs to HIV and host factors revealed that the minor allele of rs13045 remained significantly associated with NCI, along with ART use and a BDI-II score >13 82; 89 (R2 = 0.048, p < 0.0001) (Table 6), although the minor alleles of the other two coding EIF2AK3 SNVs did not. Multiple linear regression of GDS confirmed this finding: only the rs13045 minor allele (but not the other coding SNVs) remained associated with GDS, along with nadir CD+ T-cell count, BDI-II > 13, and European ancestry (R2 = 0.03, p < 0.0001) (Table 6).

View this table:
Table 6.

Multivariable analysis of the targeted sequencing sub-cohort for NCI and GDS

Association of EIF2AK3 haplotypes with NCI and GDS

Based on the complete concordance between rs867529 and rs1805165, we constructed EIF2AK3 haplotypes in the TS cohort. The frequency of these haplotypes were EIF2AK3 A/A 58.7% (n = 583), A/B 24.7% (n = 245), A/D 9.8% (n = 97), B/B 4.8% (n = 48), B/D 1.4% (n = 14), and D/D 0.5% (n = 5) (Table S6). The haplotype groups did not differ in participant characteristics. EIF2AK3 haplotypes were not associated with NCI or GDS (data not shown) or with IL-6 concentrations in CSF (Figure S1).

Discussion

One of the conundrums of the ART era is the persistence of NCI even in PWH who have achieved viral suppression and immune recovery with ART. Up to 32.7% of PWH exhibit NCI-related dysfunction in activities of daily living and even asymptomatic NCI in PWH confers substantial risk for transitioning to symptomatic status over a period of just a few years 2-6; 90. In this retrospective analysis of the well characterized CHARTER cohort, we found that previously defined coding and noncoding EIF2AK3 minor risk alleles were significantly associated with global NCI and the continuous GDS impairment measure. We also observed that the minor alleles of all three coding EIF2AK3 SNVs were associated with higher IL-6 concentrations in CSF. Furthermore, the associations between the rs13045 A minor risk allele and either global NCI or GDS remained significant after adjustment for other covariates in multivariable models. The three coding EIF2AK3 minor risk alleles were associated with performance in four NC domains: motor functioning, verbal fluency, executive functioning, and learning. While recent studies have reported certain coding and noncoding EIF2AK3 SNVs as genetic risk factors in several neurodegenerative diseases, including AD and PSP 69; 70; 91, this is the first study to demonstrate an association between multiple coding and noncoding EIF2AK3 SNVs and cognition in PWH. Overall, these findings support accumulating evidence of ISR activation as a contributor to the pathogenesis of HIV in the CNS 62-64; 92-98 and implicate EIF2AK3 as a potentially important component of genetic vulnerability to NCI in PWH.

Among the four major EIF2AK3 haplotypes, haplotypes A and B encode protein products that differ by changes in two amino acids in the luminal domain (S136C, R166Q) and one amino acid in the kinase domain (S704A) of PERK (Table 1). The significant associations of minor risk alleles of EIF2AK3 coding SNVs with NC performance uncovered in the present study are likely related to differences in PERK activation, activity, or downregulation resulting from these amino acid changes. However, the impact of these EIF2AK3 SNVs on PERK kinase activity and downstream cellular events remains unclear due to contradictory findings reported by a limited number of studies. In one study, lymphoblastoid cell lines derived from EIF2AK3 haplotype B-expressing individuals, which exhibited similar baseline PERK protein levels, nonetheless displayed enhanced PERK kinase activity, as determined by peIF2α accumulation, in response to challenge with tunicamycin, which blocks N-linked glycosylation and induces ER stress 71. In contrast, another study proposed that EIF2AK3 haplotype B might be a hypomorph based on higher eIF2α phosphorylation in EIF2AK3 haplotype A-expressing cells compared to EIF2AK3 haplotype B-expressing cells, both at baseline and following treatment with thapsigargin, which inhibits the sarcoplasmic/ER Ca2+ ATPase pump 99. The association of specific EIF2AK3 SNVs with increased kinase activity and deleterious outcomes is likely cell- and context-dependent. Nonetheless, our analyses showing the significant association of the minor alleles of the three coding EIF2AK3 SNVs with NC performance corroborate our previous studies demonstrating ISR activation in the post-mortem brain tissue from ART-treated PWH 62; 63 and implicate that maladaptive signaling might be at play in the CNS of PWH harboring the minor alleles of EIF2AK3 SNVs.

In the TS analysis, only the rs13045 A allele remained significantly associated with both GDS and NCI in multivariable analyses. The rs13045 minor allele is present in both haplotypes B and D, whereas haplotype D is defined by the presence of the rs13045 A allele alone. The frequency of the rs13045 A allele is higher than the frequencies of the other two coding EIF2AK3 SNVs across different racial groups around the globe (Table S7), which might partially explain the lack of association of the other two SNVs in multivariable analysis in the present study. The number of haplotype D heterozygotes or homozygotes was small (116/992), precluding more in-depth analysis. In addition to the need for follow-up studies in larger cohorts to clarify whether haplotype D confers increased risk for NCI, mechanistic studies are also warranted to determine whether the change in amino acid 166 from arginine to glutamine in cells carrying the rs13045 A allele may facilitate weaker affinity for binding immunoglobulin protein (BiP), allowing its dissociation from PERK, with subsequent reduction in PERK kinase activation threshold.

Our multivariable analyses of the TS cohort also confirmed that a level of depressive symptoms consistent with at least mild depression (BDI-II > 13), was also significantly associated with NC performance, supporting the contribution of depression to worse NC outcomes in PWH, which that has been recently reported in the CHARTER cohort 100; 101. These results also implicate a potential interaction between the rs13045 A allele and depression, which is currently under investigation. As the most common neuropsychiatric comorbidity in PWH 7; 8, depression is associated with worse ART adherence, viral suppression 102; 103, and survival 104; 105. Although no study to date has reported a link between EIF2AK3 SNVs and depression, the expression levels of several UPR-related genes and proteins, including EIF2AK3 and PERK, are higher in adults with major depressive disorder 106; 107. In addition, depressive-like behaviors and memory impairment can be alleviated by inhibiting PERK-peIF2α signaling in animal models of depression 108-112.

The observed association between an EIF2AK3 SNV and higher IL-6 concentrations in CSF is particularly interesting since several studies have linked systemic and CNS inflammation to neuropsychiatric conditions, including worse NC performance and depressive symptoms 89; 113. This finding provides additional evidence for a potential role of PERK in neuroinflammation in several disorders including NCI in PWH 94; 114; 115.

The significant association of the minor alleles of specific EIF2AK3 SNVs with deficits in specific domains raise the possibility of a link between specific SNVs and certain NC phenotypes, including declines in verbal fluency, executive function, learning, and motor function, which have been recently described in the MWCCS 86; 116; 117. These phenotypes likely differ in viral, host, and genetic mechanisms. Intriguingly, Kolson and colleagues recently reported associations between regional brain neuroinflammation and heme oxygenase-1 (HO-1) responses in analyses that included brain tissue from autopsy and CSF from PWH taking ART 118; 119. Their findings also implicate regional HO-1 isoform expression may be associated with differences in recovery from acute synaptic injury in a primate model of lentiviral infection 120. Given the well-characterized mechanistic role of PERK and HO-1 in activating the antioxidant response 39, an interaction between EIF2AK3 SNVs and regional susceptibility to oxidative stress might partially contribute to the observed associations of specific minor alleles of EIF2AK3 SNVs with NC phenotypes.

The construction of the EIF2AK3 haplotypes in the TS cohort revealed that the frequencies of specific haplotypes were similar to those reported in the general population, supporting that our findings may be generalizable (Table S6). The comparison of domain-specific deficit scores among groups categorized according to haplotypes suggest that certain haplotypes might be associated with deficits in certain domains (Table S8); however, the number of participants in certain groups was low, precluding further statistical analyses. Future studies are warranted in other, larger cohorts such as the MWCCS, which has notable differences including greater inclusion of women and people without HIV as well as a different distribution of ancestry, to determine the potential role of EIF2AK3 as a genetic risk factor for NCI in PWH.

Our retrospective analysis of the CHARTER GWAS data revealed that the minor alleles of the three noncoding EIF2AK3 SNVs, which were in strong linkage disequilibrium with those of the three coding EIF2AK3 SNVs, were also significantly associated with GDS and NCI. The impact of these noncoding SNVs on PERK expression, function or stability is unclear, although they have previously been linked to increased risk for PSP 70. All three noncoding SNVs are located in the intronic regions of EIF2AK3 and may result in the formation of alternative transcripts leading to RNA species or protein isoforms with altered stability or function, which warrants further investigation.

In light of the evidence showing increased or sustained PERK activity as detrimental to several critical cellular pathways in a wide range of conditions 55; 56; 59; 61; 72; 74; 75, we propose that minor alleles of SNVs associated with increased EIF2AK3 activity in response to stress might be a predictive risk factor for NCI in PWH. Aging-related comorbid diseases may cause sustained ISR activation via PERK 64; 72; 92; 95; 121; 122 that may further increase the risk for NCI in PWH.

Our findings raise several fundamental questions that should be addressed before establishing EIF2AK3 as a risk factor for NCI in PWH. First, the regulation and kinase activity of disease-associated EIF2AK3 SNVs should be described. Second, mechanisms underlying the association of specific EIF2AK3 SNVs with deleterious cellular responses to disease-relevant stressors should be elucidated in pertinent cellular contexts. Furthermore, whether the observed association of these SNVs with specific domains can be replicated and used to reliably identify specific NC phenotypes should be clarified. Future studies should also explore the relationship of EIF2AK3 SNVs with molecular and imaging biomarkers of NCI in PWH. These studies should assess their contribution to a polygenic risk score as part of a precision medicine approach to identify phenotypes and specific populations who may specifically benefit from adjunctive therapies such as modulators of PERK and endogenous antioxidant response during the best therapeutic window, soon after HIV diagnosis.

The present study has several limitations that should be addressed in future studies. First, the study cohort was relatively small for a genetics study. However, the distributions of both noncoding and coding EIF2AK3 SNVs in the CHARTER cohort were similar to those reported in larger GWASs 70. Additionally, the concordance among the noncoding and coding EIF2AK3 SNVs followed the expected pattern reported in the general population. Second, due to the low number of cases with some haplotypes, we were unable to examine the relationship of EIF2AK3 haplotypes with CSF IL-6 concentrations or BDI-II scores. The cross-sectional design precludes the inference of a causal relationship between EIF2AK3 haplotypes and NC impairment. Studies in animal models are warranted to reveal the mechanistic underpinnings of the observed associations. Finally, the models did not explain substantial variance in GDS or NCI. While this is true, the effect size for EIF2AK3 SNVs was similar in magnitude to effect sizes attributable to ART use, neuropsychiatric comorbidities, and other covariates, highlighting the potential importance of this genetic vulnerability.

In summary, the observed associations of minor alleles of EIF2AK3 SNVs with NCI, albeit small-to-medium in size, were present in multivariable analyses, raising the possibility of specific SNVs in EIF2AK3, and perhaps other ISR-related genes, as an important component of genetic vulnerability in PWH. Determination of host factors that are predictive for NC phenotypes early in the course of HIV disease might enable more effective preventive and therapeutic interventions for NC disorders.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Supplemental Data

Supplemental data include one figure and eight tables.

Declaration of interests

All authors declare that they have no relevant disclosures or conflicts of interest.

Funding

This project was supported by the following grants: R01 MH126773 and R01 MH098742 (KJS), R01 MH109382 (KJS, CAE), UG3NS104095 NINDS (GDS); N01 MH22005, HHSN271201000036C, HHSN271201000030C, and R01 MH107345 (CHARTER Study: SLL, RJE, RKH, IG, DRF); R01MH095621 (AK).

Authors’ contributions

CAE performed targeted sequencing and analyses of coding SNVs and haplotypes, wrote the first draft of the manuscript. SB provided intellectual feedback and edited the manuscript. BD performed targeted sequencing. AK provided intellectual feedback, and edited the manuscript. AB provided intellectual feedback and edited the manuscript. DRF provided intellectual feedback and edited the manuscript. GDS provided intellectual feedback and edited the manuscript. RKH provided intellectual feedback and edited the manuscript. IG served as PI of CHARTER and was involved in design, obtaining funding, and intellectual contribution. SLL and RJE designed, obtained funding for, and conducted the CHARTER project and edited the manuscript. SLE performed analyses of noncoding SNVs and his lab also performed the IL-6 assays. KJS obtained funding for the study, performed analyses of coding SNV and haplotypes, and edited the manuscript.

Acknowledgments

The CNS HIV Anti-Retroviral Therapy Effects Research was supported by awards N01 MH22005, HHSN271201000036C, HHSN271201000030C, and R01 MH107345 from the National Institutes of Health.

The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) group is affiliated with Johns Hopkins University; the Icahn School of Medicine at Mount Sinai; University of California, San Diego; University of Texas, Galveston; University of Washington, Seattle; Washington University, St. Louis; and is headquartered at the University of California, San Diego and includes: Directors: Robert K. Heaton, Ph.D., Scott L. Letendre, M.D.; Center Manager: Donald Franklin, Jr.; Coordinating Center: Brookie Best, Pharm.D., Debra Cookson, M.P.H, Clint Cushman, Matthew Dawson, Ronald J. Ellis, M.D., Ph.D., Christine Fennema Notestine, Ph.D., Sara Gianella Weibel, M.D., Igor Grant, M.D., Thomas D. Marcotte, Ph.D. Jennifer Marquie-Beck, M.P.H., Florin Vaida, Ph.D.; Johns Hopkins University Site: Ned Sacktor, M.D. (P.I.), Vincent Rogalski; Icahn School of Medicine at Mount Sinai Site: Susan Morgello, M.D. (P.I.), Letty Mintz, N.P.; University of California, San Diego Site: J. Allen McCutchan, M.D. (P.I.); University of Washington, Seattle Site: Ann Collier, M.D. (Co-P.I.) and Christina Marra, M.D. (Co-P.I.), Sher Storey, PA-C.; University of Texas, Galveston Site: Benjamin Gelman, M.D., Ph.D. (P.I.), Eleanor Head, R.N., B.S.N.; and Washington University, St. Louis Site: David Clifford, M.D. (P.I.), Mengesha Teshome, M.D.

The views expressed in this article are those of the authors and do not reflect the official policy or position of the United States Government.

References

  1. 1.↵
    Valcour, V.G. (2013). HIV, aging, and cognition: emerging issues. Topics in antiviral medicine 21, 119–123.
    OpenUrl
  2. 2.↵
    Heaton, R.K., Franklin, D.R., Jr.., Deutsch, R., Letendre, S., Ellis, R.J., Casaletto, K., Marquine, M.J., Woods, S.P., Vaida, F., Atkinson, J.H., et al. (2015). Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 60, 473–480.
    OpenUrlCrossRefPubMed
  3. 3.
    Cysique, L.A., Maruff, P., and Brew, B.J. (2004). Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre-and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 10, 350–357.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.
    Alisky, J.M. (2007). The coming problem of HIV-associated Alzheimer’s disease. Medical hypotheses 69, 1140–1143.
    OpenUrlPubMed
  5. 5.↵
    Sakamoto, M., Marcotte, T.D., Umlauf, A., Franklin, D., Jr.., Heaton, R.K., Ellis, R.J., Letendre, S., Alexander, T., McCutchan, J.A., Morgan, E.E., et al. (2013). Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. Journal of acquired immune deficiency syndromes (1999) 62, 36–42.
    OpenUrl
  6. 6.↵
    Grant, I., Franklin, D.R., Jr.., Deutsch, R., Woods, S.P., Vaida, F., Ellis, R.J., Letendre, S.L., Marcotte, T.D., Atkinson, J.H., Collier, A.C., et al. (2014). Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology 82, 2055–2062.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Antelman, G., Kaaya, S., Wei, R., Mbwambo, J., Msamanga, G.I., Fawzi, W.W., and Fawzi, M.C.S. (2007). Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania. Journal of acquired immune deficiency syndromes (1999) 44, 470.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Bing, E.G., Burnam, M.A., Longshore, D., Fleishman, J.A., Sherbourne, C.D., London, A.S., Turner, B.J., Eggan, F., Beckman, R., and Vitiello, B. (2001). Psychiatric disorders and drug use among human immunodeficiency virus–infected adults in the United States. Archives of general psychiatry 58, 721–728.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.
    Orlando, M., Burnam, M.A., Beckman, R., Morton, S.C., London, A.S., Bing, E.G., and Fleishman, J.A. (2002). Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV cost and services utilization study. International Journal of Methods in Psychiatric Research 11, 75–82.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.
    Cook, J.A., Burke-Miller, J.K., Steigman, P.J., Schwartz, R.M., Hessol, N.A., Milam, J., Merenstein, D.J., Anastos, K., Golub, E.T., and Cohen, M.H. (2018). Prevalence, comorbidity, and correlates of psychiatric and substance use disorders and associations with HIV risk behaviors in a multisite cohort of women living with HIV. AIDS and Behavior 22, 3141–3154.
    OpenUrlPubMed
  11. 11.↵
    Williams, D.W., Li, Y., Dastgheyb, R., Fitzgerald, K.C., Maki, P.M., Spence, A.B., Gustafson, D.R., Milam, J., Sharma, A., and Adimora, A.A. (2020). Associations between antiretroviral drugs on depressive symptomatology in homogenous subgroups of women with HIV. Journal of Neuroimmune Pharmacology, 1–14.
  12. 12.
    Brew, B.J., Crowe, S.M., Landay, A., Cysique, L.A., and Guillemin, G. (2009). Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol 4, 163–174.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.
    Valcour, V., Paul, R., Neuhaus, J., and Shikuma, C. (2011). The effects of age and HIV on neuropsychological performance. Journal of the International Neuropsychological Society 17, 190–195.
    OpenUrlCrossRefPubMed
  14. 14.↵
    Pence, B.W., Miller, W.C., Whetten, K., Eron, J.J., and Gaynes, B.N. (2006). Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 42, 298–306.
    OpenUrl
  15. 15.↵
    Dore, G.J., McDonald, A., Li, Y., Kaldor, J.M., and Brew, B.J. (2003). Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (London, England) 17, 1539–1545.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.
    Anthony, I.C., Ramage, S.N., Carnie, F.W., Simmonds, P., and Bell, J.E. (2005). Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 64, 529–536.
    OpenUrlCrossRefPubMed
  17. 17.↵
    Mind Exchange Working, G. (2013). Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 56, 1004–1017.
    OpenUrlCrossRefPubMed
  18. 18.
    Harezlak, J., Buchthal, S., Taylor, M., Schifitto, G., Zhong, J., Daar, E., Alger, J., Singer, E., Campbell, T., Yiannoutsos, C., et al. (2011). Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS (London, England).
  19. 19.
    Nath, A., and Sacktor, N. (2006). Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol 19, 358–361.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.
    Tozzi, V., Balestra, P., Bellagamba, R., Corpolongo, A., Salvatori, M.F., Visco-Comandini, U., Vlassi, C., Giulianelli, M., Galgani, S., Antinori, A., et al. (2007). Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. Journal of acquired immune deficiency syndromes (1999) 45, 174–182.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.
    Vandergeeten, C., Fromentin, R., and Chomont, N. (2012). The role of cytokines in the establishment, persistence and eradication of the HIV reservoir. Cytokine Growth Factor Rev 23, 143–149.
    OpenUrlCrossRefPubMed
  22. 22.
    Kaul, M., Zheng, J., Okamoto, S., Gendelman, H.E., and Lipton, S.A. (2005). HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 12 Suppl 1, 878–892.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.
    Martin-Thormeyer, E.M., and Paul, R.H. (2009). Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev 19, 215–231.
    OpenUrlCrossRefPubMed
  24. 24.
    Turner, J., Bansi, L., Gilson, R., Gazzard, B., Walsh, J., Pillay, D., Orkin, C., Phillips, A., Easterbrook, P., Johnson, M., et al. (2010). The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat 17, 569–577.
    OpenUrlPubMed
  25. 25.
    Spengler, U. (2011). Management of end-stage liver disease in HIV/hepatitis C virus co-infection. Curr Opin HIV AIDS 6, 527–533.
    OpenUrlPubMed
  26. 26.
    Hua, X., Boyle, C.P., Harezlak, J., Tate, D.F., Yiannoutsos, C.T., Cohen, R., Schifitto, G., Gongvatana, A., Zhong, J., Zhu, T., et al. (2013). Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment. NeuroImage Clinical 3, 132–142.
    OpenUrl
  27. 27.
    Cohen, R.A., Harezlak, J., Schifitto, G., Hana, G., Clark, U., Gongvatana, A., Paul, R., Taylor, M., Thompson, P., Alger, J., et al. (2010). Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol 16, 25–32.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Thompson, M.A., Aberg, J.A., Cahn, P., Montaner, J.S., Rizzardini, G., Telenti, A., Gatell, J.M., Gunthard, H.F., Hammer, S.M., Hirsch, M.S., et al. (2010). Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304, 321–333.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    McGuire, J.L., Barrett, J.S., Vezina, H.E., Spitsin, S., and Douglas, S.D. (2014). Adjuvant therapies for HIV-associated neurocognitive disorders. Annals of clinical and translational neurology 1, 938–952.
    OpenUrl
  30. 30.↵
    Brabers, N.A.C.H., and Nottet, H.S.L.M. (2006). Role of the pro-inflammatory cytokines TNF-alpha and IL-1 beta in HIV-associated dementia. European Journal of Clinical Investigation 36, 447–458.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.
    Levine, A.J., Singer, E.J., Sinsheimer, J.S., Hinkin, C.H., Papp, J., Dandekar, S., Giovanelli, A., and Shapshak, P. (2009). CCL3 genotype and current depression increase risk of HIV-associated dementia. Neurobehavioral HIV medicine 1, 1–7.
    OpenUrl
  32. 32.
    Levine, A.J., Reynolds, S., Cox, C., Miller, E.N., Sinsheimer, J.S., Becker, J.T., Martin, E., and Sacktor, N. (2014). The longitudinal and interactive effects of HIV status, stimulant use, and host genotype upon neurocognitive functioning. Journal of Neurovirology 20, 243–257.
    OpenUrl
  33. 33.
    Levine, A., Reynolds, S., Cox, C., Miller, E., Service, S., Sacktor, N., Becker, J., and Martin, E. (2012). Longitudinal analysis of interactive effects of host genotype, stimulant use, and HIV status upon neurocognitive functioning. Journal of Neurovirology 18, 60–61.
    OpenUrl
  34. 34.
    Andres, M.A., Feger, U., Nath, A., Munsaka, S., Jiang, C.S., and Chang, L. (2011). APOE epsilon 4 allele and CSF APOE on Cognition in HIV-Infected Subjects. Journal of Neuroimmune Pharmacology 6, 389–398.
    OpenUrl
  35. 35.
    Hoare, J., Westgarth-Taylor, J., Fouche, J.P., Combrinck, M., Spottiswoode, B., Stein, D.J., and Joska, J.A. (2013). Relationship between apolipoprotein E4 genotype and white matter integrity in HIV-positive young adults in South Africa. Eur Arch Psy Clin N 263, 189–195.
    OpenUrl
  36. 36.
    Pemberton, L.A., Stone, E., Price, P., van Bockxmeer, F., and Brew, B.J. (2008). The relationship between ApoE, TNFA, IL1a, IL1b and IL12b genes and HIV-1-associated dementia. HIV Med 9, 677–680.
    OpenUrlCrossRefPubMed
  37. 37.↵
    Levine, A.J., Service, S., Miller, E.N., Reynolds, S.M., Singer, E.J., Shapshak, P., Martin, E.M., Sacktor, N., Becker, J.T., Jacobson, L.P., et al. (2012). Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults. American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 159B, 669–683.
    OpenUrl
  38. 38.↵
    Cullinan, S.B., and Diehl, J.A. (2006). Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. [Review] [177 refs]. Journal of Biochemistry and Cell Biology 38, 317–332.
    OpenUrl
  39. 39.↵
    Cullinan, S.B., and Diehl, J.A. (2004). PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem 279, 20108–20117.
    OpenUrlAbstract/FREE Full Text
  40. 40.
    Kaufman, R.J., Back, S.H., Song, B., Han, J., and Hassler, J. (2010). The unfolded protein response is required to maintain the integrity of the endoplasmic reticulum, prevent oxidative stress and preserve differentiation in beta-cells. Diabetes, obesity & metabolism 12 Suppl 2, 99–107.
    OpenUrl
  41. 41.
    Kudo, T., Katayama, T., Imaizumi, K., Yasuda, Y., Yatera, M., Okochi, M., Tohyama, M., and Takeda, M. (2002). The unfolded protein response is involved in the pathology of Alzheimer’s disease. Ann N Y Acad Sci 977, 349–355.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.
    Manga, P., Bis, S., Knoll, K., Perez, B., and Orlow, S.J. (2010). The unfolded protein response in melanocytes: activation in response to chemical stressors of the endoplasmic reticulum and tyrosinase misfolding. Pigment cell & melanoma research 23, 627–634.
    OpenUrl
  43. 43.
    Thomas, M., Yu, Z., Dadgar, N., Varambally, S., Yu, J., Chinnaiyan, A.M., and Lieberman, A.P. (2005). The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor. J Biol Chem 280, 21264–21271.
    OpenUrlAbstract/FREE Full Text
  44. 44.
    Back, S.H., Kang, S.W., Han, J., and Chung, H.T. (2012). Endoplasmic reticulum stress in the beta-cell pathogenesis of type 2 diabetes. Experimental diabetes research 2012, 618396.
    OpenUrlPubMed
  45. 45.
    Fels, D.R., and Koumenis, C. (2006). The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol Ther 5, 723–728.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.
    Halliday, M., Radford, H., Sekine, Y., Moreno, J., Verity, N., le Quesne, J., Ortori, C.A., Barrett, D.A., Fromont, C., Fischer, P.M., et al. (2015). Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. Cell Death Dis 6, e1672.
    OpenUrlCrossRefPubMed
  47. 47.
    Tsutsumi, A., Motoshima, H., Kondo, T., Kawasaki, S., Matsumura, T., Hanatani, S., Igata, M., Ishii, N., Kinoshita, H., Kawashima, J., et al. (2011). Caloric restriction decreases ER stress in liver and adipose tissue in ob/ob mice. Biochem Biophys Res Commun 404, 339–344.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.
    Volmer, R., and Ron, D. (2015). Lipid-dependent regulation of the unfolded protein response. Current opinion in cell biology 33, 67–73.
    OpenUrlCrossRefPubMed
  49. 49.
    Volmer, R., van der Ploeg, K., and Ron, D. (2013). Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains. Proc Natl Acad Sci U S A 110, 4628–4633.
    OpenUrlAbstract/FREE Full Text
  50. 50.
    Zheng, Z., Zhang, C., and Zhang, K. (2011). Measurement of ER stress response and inflammation in the mouse model of nonalcoholic fatty liver disease. Methods Enzymol 489, 329–348.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    Pakos-Zebrucka, K., Koryga, I., Mnich, K., Ljujic, M., Samali, A., and Gorman, A.M. (2016). The integrated stress response. EMBO reports 17, 1374–1395.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    Bertolotti, A., Zhang, Y., Hendershot, L.M., Harding, H.P., and Ron, D. (2000). Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nature cell biology 2, 326–332.
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.↵
    Ishii, T., Itoh, K., Ruiz, E., Leake, D.S., Unoki, H., Yamamoto, M., and Mann, G.E. (2004). Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circulation research 94, 609–616.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    Cullinan, S.B., Zhang, D., Hannink, M., Arvisais, E., Kaufman, R.J., and Diehl, J.A. (2003). Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Molecular and Cellular Biology 23, 7198–7209.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    Salminen, A., Kauppinen, A., Suuronen, T., Kaarniranta, K., and Ojala, J. (2009). ER stress in Alzheimer’s disease: a novel neuronal trigger for inflammation and Alzheimer’s pathology. J Neuroinflammation 6, 41.
    OpenUrlCrossRefPubMed
  56. 56.↵
    O’Connor, T., Sadleir, K.R., Maus, E., Velliquette, R.A., Zhao, J., Cole, S.L., Eimer, W.A., Hitt, B., Bembinster, L.A., Lammich, S., et al. (2008). Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 60, 988–1009.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    Kania, E., Pajak, B., and Orzechowski, A. (2015). Calcium Homeostasis and ER Stress in Control of Autophagy in Cancer Cells. BioMed research international 2015, 352794.
    OpenUrl
  58. 58.
    Wang, R., Munoz, E.E., Zhu, S., McGrath, B.C., and Cavener, D.R. (2014). Perk gene dosage regulates glucose homeostasis by modulating pancreatic beta-cell functions. PLoS One 9, e99684.
    OpenUrlCrossRefPubMed
  59. 59.↵
    Zhang, K.Z., and Kaufman, R.J. (2008). From endoplasmic-reticulum stress to the inflammatory response. Nature 454, 455–462.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.
    Verfaillie, T., Garg, A.D., and Agostinis, P. (2013). Targeting ER stress induced apoptosis and inflammation in cancer. Cancer letters 332, 249–264.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    Hotamisligil, G.S. (2006). Inflammation and metabolic disorders. Nature 444, 860–867.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    Akay, C., Lindl, K.A., Shyam, N., Nabet, B., Goenaga-Vazquez, Y., Ruzbarsky, J., Wang, Y., Kolson, D.L., and Jordan-Sciutto, K.L. (2012). Activation status of integrated stress response pathways in neurones and astrocytes of HIV-associated neurocognitive disorders (HAND) cortex. Neuropathol Appl Neurobiol 38, 175–200.
    OpenUrlCrossRefPubMed
  63. 63.↵
    Lindl, K.A., Akay, C., Wang, Y., White, M.G., and Jordan-Sciutto, K.L. (2007). Expression of the endoplasmic reticulum stress response marker, BiP, in the central nervous system of HIV-positive individuals. Neuropathol Appl Neurobiol 33, 658–669.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    Gannon, P.J., Akay-Espinoza, C., Yee, A.C., Briand, L.A., Erickson, M.A., Gelman, B.B., Gao, Y., Haughey, N.J., Zink, M.C., Clements, J.E., et al. (2017). HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via beta-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. Am J Pathol 187, 91–109.
    OpenUrlCrossRefPubMed
  65. 65.
    Hetz, C., and Saxena, S. (2017). ER stress and the unfolded protein response in neurodegeneration. Nat Rev Neurol 13, 477–491.
    OpenUrlCrossRefPubMed
  66. 66.
    Colla, E., Jensen, P.H., Pletnikova, O., Troncoso, J.C., Glabe, C., and Lee, M.K. (2012). Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. Journal of Neuroscience 32, 3301–3305.
    OpenUrlAbstract/FREE Full Text
  67. 67.
    Atkin, J.D., Farg, M.A., Walker, A.K., McLean, C., Tomas, D., and Horne, M.K. (2008). Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. Neurobiology of disease 30, 400–407.
    OpenUrlCrossRefPubMed
  68. 68.↵
    Hoozemans, J.J., van Haastert, E.S., Nijholt, D.A., Rozemuller, A.J., Eikelenboom, P., and Scheper, W. (2009). The unfolded protein response is activated in pretangle neurons in Alzheimer’s disease hippocampus. Am J Pathol 174, 1241–1251.
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.↵
    Hoglinger, G.U., Melhem, N.M., Dickson, D.W., Sleiman, P.M., Wang, L.S., Klei, L., Rademakers, R., de Silva, R., Litvan, I., Riley, D.E., et al. (2011). Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature genetics 43, 699–705.
    OpenUrlCrossRefPubMed
  70. 70.↵
    Stutzbach, L.D., Xie, S.X., Naj, A.C., Albin, R., Gilman, S., Group, P.S.P.G.S., Lee, V.M., Trojanowski, J.Q., Devlin, B., and Schellenberg, G.D. (2013). The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer’s disease. Acta neuropathologica communications 1, 31.
    OpenUrl
  71. 71.↵
    Liu, J., Hoppman, N., O’Connell, J.R., Wang, H., Streeten, E.A., McLenithan, J.C., Mitchell, B.D., and Shuldiner, A.R. (2012). A functional haplotype in EIF2AK3, an ER stress sensor, is associated with lower bone mineral density. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 27, 331–341.
    OpenUrl
  72. 72.↵
    Devi, L., and Ohno, M. (2014). PERK mediates eIF2alpha phosphorylation responsible for BACE1 elevation, CREB dysfunction and neurodegeneration in a mouse model of Alzheimer’s disease. Neurobiol Aging 35, 2272–2281.
    OpenUrlCrossRefPubMed
  73. 73.
    Li, J.Q., Yu, J.T., Jiang, T., and Tan, L. (2015). Endoplasmic reticulum dysfunction in Alzheimer’s disease. Molecular neurobiology 51, 383–395.
    OpenUrl
  74. 74.↵
    Ma, T., Trinh, M.A., Wexler, A.J., Bourbon, C., Gatti, E., Pierre, P., Cavener, D.R., and Klann, E. (2013). Suppression of eIF2α kinases alleviates Alzheimer’s disease–related plasticity and memory deficits. Nature neuroscience 16, 1299.
    OpenUrlCrossRefPubMed
  75. 75.↵
    Moreno, J.A., Halliday, M., Molloy, C., Radford, H., Verity, N., Axten, J.M., Ortori, C.A., Willis, A.E., Fischer, P.M., Barrett, D.A., et al. (2013). Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Science translational medicine 5, 206ra138.
    OpenUrlAbstract/FREE Full Text
  76. 76.
    Axten, J.M., Romeril, S.P., Shu, A., Ralph, J., Medina, J.R., Feng, Y., Li, W.H., Grant, S.W., Heerding, D.A., Minthorn, E., et al. (2013). Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development. ACS medicinal chemistry letters 4, 964–968.
    OpenUrl
  77. 77.
    Mercado, G., Castillo, V., Soto, P., López, N., Axten, J.M., Sardi, S.P., Hoozemans, J.J., and Hetz, C. (2018). Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson’s disease. Neurobiology of disease 112, 136–148.
    OpenUrl
  78. 78.
    Vaccaro, A., Patten, S.A., Aggad, D., Julien, C., Maios, C., Kabashi, E., Drapeau, P., and Parker, J.A. (2013). Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. Neurobiology of disease 55, 64–75.
    OpenUrlCrossRefPubMed
  79. 79.↵
    Rubovitch, V., Barak, S., Rachmany, L., Goldstein, R.B., Zilberstein, Y., and Pick, C.G. (2015). The neuroprotective effect of salubrinal in a mouse model of traumatic brain injury. Neuromolecular medicine 17, 58–70.
    OpenUrlCrossRefPubMed
  80. 80.↵
    Heaton, R.K., Franklin, D.R., Ellis, R.J., McCutchan, J.A., Letendre, S.L., Leblanc, S., Corkran, S.H., Duarte, N.A., Clifford, D.B., Woods, S.P., et al. (2010). HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol.
  81. 81.↵
    Carey, C.L., Woods, S.P., Gonzalez, R., Conover, E., Marcotte, T.D., Grant, I., and Heaton, R.K. (2004). Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. Journal of clinical and experimental neuropsychology 26, 307–319.
    OpenUrlCrossRefPubMedWeb of Science
  82. 82.↵
    Beck, A.T., Steer, R.A., Ball, R., and Ranieri, W.F. (1996). Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. Journal of personality assessment 67, 588–597.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    Vecchio, A., Robertson, K., Saylor, D., Nakigozi, G., Nakasujja, N., Kisakye, A., Batte, J., Mayanja, R., Anok, A., and Reynolds, S.J. (2020). Neurocognitive Effects of Antiretroviral Initiation Among People Living With HIV in Rural Uganda. JAIDS Journal of Acquired Immune Deficiency Syndromes 84, 534–542.
    OpenUrl
  84. 84.
    Meyer, V.J., Rubin, L.H., Martin, E., Weber, K.M., Cohen, M.H., Golub, E.T., Valcour, V., Young, M.A., Crystal, H., Anastos, K., et al. (2013). HIV and recent illicit drug use interact to affect verbal memory in women. Journal of acquired immune deficiency syndromes (1999) 63, 67–76.
    OpenUrlCrossRef
  85. 85.
    Rubin, L.H., Xu, Y., Norris, P.J., Wang, X., Dastgheyb, R., Fitzgerald, K.C., Keating, S.M., Kaplan, R.C., Maki, P.M., and Anastos, K. (2020). Early Inflammatory Signatures Predict Subsequent Cognition in Long-Term Virally Suppressed Women With HIV. Frontiers in Integrative Neuroscience 14, 20.
    OpenUrl
  86. 86.↵
    Dastgheyb, R.M., Sacktor, N., Franklin, D., Letendre, S., Marcotte, T., Heaton, R., Grant, I., McArthur, J.C., Rubin, L.H., and Haughey, N.J. (2019). Cognitive Trajectory Phenotypes in Human Immunodeficiency Virus–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 82, 61–70.
    OpenUrl
  87. 87.↵
    Lu, H., Surkan, P.J., Irwin, M.R., Treisman, G.J., Breen, E.C., Sacktor, N., Stall, R., Wolinsky, S.M., Jacobson, L.P., and Abraham, A.G. (2019). Inflammation and Risk of Depression in HIV: Prospective Findings From the Multicenter AIDS Cohort Study. American journal of epidemiology 188, 1994–2003.
    OpenUrl
  88. 88.↵
    Oliveira, M.F., Chaillon, A., Nakazawa, M., Vargas, M., Letendre, S.L., Strain, M.C., Ellis, R.J., Morris, S., Little, S.J., and Smith, D.M. (2017). Early antiretroviral therapy is associated with lower HIV DNA molecular diversity and lower inflammation in cerebrospinal fluid but does not prevent the establishment of compartmentalized HIV DNA populations. PLoS pathogens 13, e1006112.
    OpenUrlCrossRef
  89. 89.↵
    Ellis, R.J., Letendre, S.L., Atkinson, J.H., Clifford, D., Collier, A.C., Gelman, B.B., Marra, C., McCutchan, J.A., Morgello, S., and Sacktor, N. (2020). Higher levels of plasma inflammation biomarkers are associated with depressed mood and quality of life in aging, virally suppressed men, but not women, with HIV. Brain, Behavior, & Immunity-Health 7, 100121.
    OpenUrl
  90. 90.↵
    Wei, J., Hou, J., Su, B., Jiang, T., Guo, C., Wang, W., Zhang, Y., Chang, B., Wu, H., and Zhang, T. (2020). The prevalence of Frascati-criteria-based HIV-associated neurocognitive disorder (HAND) in HIV-infected adults: a systematic review and meta-analysis. Frontiers in neurology, 1613.
  91. 91.↵
    Wong, T.H., van der Lee, S.J., van Rooij, J.G.J., Meeter, L.H.H., Frick, P., Melhem, S., Seelaar, H., Ikram, M.A., Rozemuller, A.J., Holstege, H., et al. (2019). EIF2AK3 variants in Dutch patients with Alzheimer’s disease. Neurobiol Aging 73, 229 e211–229 e218.
    OpenUrl
  92. 92.↵
    Akay, C., Cooper, M., Odeleye, A., Jensen, B.K., White, M.G., Vassoler, F., Gannon, P.J., Mankowski, J., Dorsey, J.L., Buch, A.M., et al. (2014). Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. J Neurovirol 20, 39–53.
    OpenUrlCrossRefPubMedWeb of Science
  93. 93.
    Bond, S., Lopez-Lloreda, C., Gannon, P.J., Akay-Espinoza, C., and Jordan-Sciutto, K.L. (2020). The Integrated Stress Response and Phosphorylated Eukaryotic Initiation Factor 2alpha in Neurodegeneration. J Neuropathol Exp Neurol.
  94. 94.↵
    Roth, L.M., Akay-Espinoza, C., Grinspan, J.B., and Jordan-Sciutto, K.L. (2021). HIV-induced neuroinflammation inhibits oligodendrocyte maturation via glutamate-dependent activation of the PERK arm of the integrated stress response. Glia.
  95. 95.↵
    Stern, A.L., Lee, R.N., Panvelker, N., Li, J., Harowitz, J., Jordan-Sciutto, K.L., and Akay-Espinoza, C. (2017). Differential Effects of Antiretroviral Drugs on Neurons In Vitro: Roles for Oxidative Stress and Integrated Stress Response. J Neuroimmune Pharmacol.
  96. 96.
    Ryan, S.K., Gonzalez, M.V., Garifallou, J.P., Bennett, F.C., Williams, K.S., Sotuyo, N.P., Mironets, E., Cook, K., Hakonarson, H., Anderson, S.A., et al. (2020). Neuroinflammation and EIF2 Signaling Persist despite Antiretroviral Treatment in an hiPSC Tri-culture Model of HIV Infection. Stem Cell Reports.
  97. 97.
    Ma, R., Yang, L., Niu, F., and Buch, S. (2016). HIV Tat-Mediated Induction of Human Brain Microvascular Endothelial Cell Apoptosis Involves Endoplasmic Reticulum Stress and Mitochondrial Dysfunction. Molecular neurobiology 53, 132–142.
    OpenUrl
  98. 98.↵
    Fan, Y., and He, J.J. (2016). HIV-1 Tat Induces Unfolded Protein Response and Endoplasmic Reticulum Stress in Astrocytes and Causes Neurotoxicity through Glial Fibrillary Acidic Protein (GFAP) Activation and Aggregation. J Biol Chem 291, 22819–22829.
    OpenUrlAbstract/FREE Full Text
  99. 99.↵
    Yuan, S.H., Hiramatsu, N., Liu, Q., Sun, X.V., Lenh, D., Chan, P., Chiang, K., Koo, E.H., Kao, A.W., and Litvan, I. (2018). Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress. Human molecular genetics 27, 3951–3963.
    OpenUrlCrossRefPubMed
  100. 100.↵
    Paolillo, E.W., Pasipanodya, E.C., Moore, R.C., Pence, B.W., Atkinson, J.H., Grelotti, D.J., Grant, I., Heaton, R.K., and Moore, D.J. (2020). Cumulative Burden of Depression and Neurocognitive Decline Among Persons With HIV: A Longitudinal Study. Journal of acquired immune deficiency syndromes (1999) 84, 304–312.
    OpenUrl
  101. 101.↵
    Saloner, R., Paolillo, E.W., Heaton, R.K., Grelotti, D.J., Stein, M.B., Miller, A.H., Atkinson, J.H., Letendre, S.L., Ellis, R.J., Grant, I., et al. (2021). Chronically elevated depressive symptoms interact with acute increases in inflammation to predict worse neurocognition among people with HIV. Journal of neurovirology 27, 160–167.
    OpenUrl
  102. 102.↵
    Ickovics, J.R., Hamburger, M.E., Vlahov, D., Schoenbaum, E.E., Schuman, P., Boland, R.J., Moore, J., Group, H.E.R.S., and Group, H.E.R.S. (2001). Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. Jama 285, 1466–1474.
    OpenUrlCrossRefPubMedWeb of Science
  103. 103.↵
    Ironson, G., O’Cleirigh, C., Fletcher, M.A., Laurenceau, J.P., Balbin, E., Klimas, N., Schneiderman, N., and Solomon, G. (2005). Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosomatic medicine 67, 1013.
    OpenUrlAbstract/FREE Full Text
  104. 104.↵
    French, A.L., Gawel, S.H., Hershow, R., Benning, L., Hessol, N.A., Levine, A.M., Anastos, K., Augenbraun, M., and Cohen, M.H. (2009). Trends in mortality and causes of death among women with HIV in the US: A ten-year study. Journal of acquired immune deficiency syndromes (1999) 51, 399.
    OpenUrlCrossRefPubMedWeb of Science
  105. 105.↵
    Villes, V., Spire, B., Lewden, C., Perronne, C., Besnier, J.-M., Garré, M., Chêne, G., Leport, C., Carrieri, M.P., and Le Moings, V. (2007). The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice. Antiviral therapy 12, 1067.
    OpenUrlPubMedWeb of Science
  106. 106.↵
    Bown, C., Wang, J.-F., MacQueen, G., and Young, L.T. (2000). Increased temporal cortex ER stress proteins in depressed subjects who died by suicide. Neuropsychopharmacology 22, 327–332.
    OpenUrlCrossRefPubMedWeb of Science
  107. 107.↵
    Nevell, L., Zhang, K., Aiello, A.E., Koenen, K., Galea, S., Soliven, R., Zhang, C., Wildman, D.E., and Uddin, M. (2014). Elevated systemic expression of ER stress related genes is associated with stress-related mental disorders in the Detroit Neighborhood Health Study. Psychoneuroendocrinology 43, 62–70.
    OpenUrl
  108. 108.↵
    Sharma, V., Ounallah-Saad, H., Chakraborty, D., Hleihil, M., Sood, R., Barrera, I., Edry, E., Chandran, S.K., de Leon, S.B.T., and Kaphzan, H. (2018). Local inhibition of PERK enhances memory and reverses age-related deterioration of cognitive and neuronal properties. Journal of Neuroscience 38, 648–658.
    OpenUrlAbstract/FREE Full Text
  109. 109.
    Jangra, A., Sriram, C.S., Dwivedi, S., Gurjar, S.S., Hussain, M.I., Borah, P., and Lahkar, M. (2017). Sodium phenylbutyrate and edaravone abrogate chronic restraint stress-induced behavioral deficits: implication of oxido-nitrosative, endoplasmic reticulum stress cascade, and neuroinflammation. Cellular and molecular neurobiology 37, 65–81.
    OpenUrl
  110. 110.
    Kowalczyk, M., Majsterek, I., Galecki, P., and Talarowska, M. (2020). The role of the endoplasmic reticulum stress in depression. Psychiatria polska 54, 499–508.
    OpenUrl
  111. 111.
    Mao, J., Hu, Y., Ruan, L., Ji, Y., and Lou, Z. (2019). Role of endoplasmic reticulum stress in depression (Review). Mol Med Rep 20, 4774–4780.
    OpenUrl
  112. 112.↵
    Li, M.-X., Li, Q., Sun, X.-J., Luo, C., Li, Y., Wang, Y.-N., Chen, J., Gong, C.-Z., Li, Y.-J., and Shi, L.-P. (2019). Increased Homer1-mGluR5 mediates chronic stress-induced depressive-like behaviors and glutamatergic dysregulation via activation of PERK-eIF2α. Progress in Neuro-Psychopharmacology and Biological Psychiatry 95, 109682.
    OpenUrl
  113. 113.↵
    Sattler, F., Jiaxiu, H., Letendre, S., Wilson, C., Sanders, C., Heaton, R., Ellis, R., Franklin, D., Aldrovandi, G., and Marra, C.M. (2015). Abdominal obesity contributes to neurocognitive impairment in HIV infected patients with increased inflammation and immune activation. Journal of acquired immune deficiency syndromes (1999) 68, 281.
    OpenUrlCrossRefPubMed
  114. 114.↵
    Meares, G.P., Liu, Y., Rajbhandari, R., Qin, H., Nozell, S.E., Mobley, J.A., Corbett, J.A., and Benveniste, E.N. (2014). PERK-dependent activation of JAK1 and STAT3 contributes to endoplasmic reticulum stress-induced inflammation. Molecular and cellular biology 34, 3911–3925.
    OpenUrlAbstract/FREE Full Text
  115. 115.↵
    Lin, W., Lin, Y., Li, J., Fenstermaker, A.G., Way, S.W., Clayton, B., Jamison, S., Harding, H.P., Ron, D., and Popko, B. (2013). Oligodendrocyte-specific activation of PERK signaling protects mice against experimental autoimmune encephalomyelitis. Journal of Neuroscience 33, 5980–5991.
    OpenUrlAbstract/FREE Full Text
  116. 116.↵
    Rubin, L.H., Maki, P.M., Springer, G., Benning, L., Anastos, K., Gustafson, D., Villacres, M.C., Jiang, X., Adimora, A.A., and Waldrop-Valverde, D. (2017). Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression. Neurology 89, 1594–1603.
    OpenUrl
  117. 117.↵
    Molsberry, S.A., Cheng, Y., Kingsley, L., Jacobson, L., Levine, A.J., Martin, E., Miller, E.N., Munro, C.A., Ragin, A., and Sacktor, N. (2018). Neuropsychological phenotypes among men with and without HIV disease in the multicenter AIDS cohort study. AIDS (London, England) 32, 1679.
    OpenUrl
  118. 118.↵
    Gill, A.J., Garza, R., Ambegaokar, S.S., Gelman, B.B., and Kolson, D.L. (2018). Heme oxygenase-1 promoter region (GT)n polymorphism associates with increased neuroimmune activation and risk for encephalitis in HIV infection. J Neuroinflammation 15, 70.
    OpenUrlCrossRef
  119. 119.↵
    Garza, R., Gill, A.J., Bastien, B.L., Garcia-Mesa, Y., Gruenewald, A.L., Gelman, B.B., Tsima, B., Gross, R., Letendre, S.L., and Kolson, D.L. (2020). Heme oxygenase-1 promoter (GT) n polymorphism associates with HIV neurocognitive impairment. Neurology-Neuroimmunology Neuroinflammation 7.
  120. 120.↵
    Garcia-Mesa, Y., Garza, R., Diaz Ortiz, M.E., Gruenewald, A.L., Bastien, B.L., Lobrovich, R., Irwin, D.J., Betts, M.R., Silvestri, G., and Kolson, D.L. (2020). Regional brain recovery from acute synaptic injury in SIV-infected rhesus macaques associates with heme oxygenase isoform expression. J Virol.
  121. 121.↵
    Zhou, H., Gurley, E.C., Jarujaron, S., Ding, H., Fang, Y., Xu, Z., Pandak, W.M., Jr.., and Hylemon, P.B. (2006). HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. Am J Physiol Gastrointest Liver Physiol 291, G1071–1080.
    OpenUrlCrossRefPubMed
  122. 122.↵
    Stern, A.L., Ghura, S., Gannon, P.J., Akay-Espinoza, C., Phan, J.M., Yee, A.C., Vassar, R., Gelman, B.B., Kolson, D.L., and Jordan-Sciutto, K.L. (2018). BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism. J Neurosci 38, 4288–4300.
    OpenUrlAbstract/FREE Full Text
Back to top
Posted April 23, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Genetic variations in EIF2AK3 are associated with neurocognitive impairment in people living with HIV
Cagla Akay-Espinoza, Sarah Bond, Beth A. Dombroski, Asha Kallianpur, Ajay Bharti, Donald R. Franklin, Gerard D. Schellenberg, Robert K. Heaton, Igor Grant, Ronald J. Ellis, Scott L. Letendre, Kelly L. Jordan-Sciutto
medRxiv 2022.04.20.22273997; doi: https://doi.org/10.1101/2022.04.20.22273997
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area